TrialThe oncologist2024

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Hongmeng Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.